Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Accumulated Expenses (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Other Accumulated Expenses data on record, last reported at $2.7 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 7.87% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, down 7.87%, while the annual FY2025 figure was $2.7 million, 7.87% down from the prior year.
  • Other Accumulated Expenses reached $2.7 million in Q4 2025 per APLS's latest filing, down from $4.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $30.8 million in Q3 2023 and bottomed at $2.7 million in Q4 2025.
  • Average Other Accumulated Expenses over 5 years is $13.9 million, with a median of $13.3 million recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: rose 17.36% in 2024, then crashed 78.22% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $12.8 million in 2021, then grew by 7.88% to $13.8 million in 2022, then dropped by 11.94% to $12.2 million in 2023, then tumbled by 75.56% to $3.0 million in 2024, then decreased by 7.87% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $2.7 million in Q4 2025, $4.7 million in Q3 2025, and $5.5 million in Q2 2025.